Menu
Log in


Log in

MEMBER LOGIN

Anti–IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison

Wed, October 16, 2024 1:27 PM | Anonymous

Background: Three anti–IL-5 pathway–directed therapies are approved for use in patients with severe eosinophilic asthma (SEA); however, no head-to-head comparison data are available.

Objective: We sought to compare the efficacy of licensed doses of mepolizumab, benralizumab, and reslizumab in patients with SEA, according to baseline blood eosinophil counts.

Methods: This indirect treatment comparison (ITC) used data from a Cochrane review and independent searches. Eligible studies were randomized controlled trials in patients aged 12 years or greater with SEA. End points included annualized rate of clinically significant exacerbations and change from baseline in Asthma Control Questionnaire score and FEV1. An ITC was performed in patients with Asthma Control

https://www.jacionline.org/article/S0091-6749(18)31278-8/fulltext


CHICAGO ASTHMA CONSORTIUM
400 E. Randolph St., Suite 3115, Chicago, IL 60601
Phone: 888-268-8334 Fax: 312-540-9900

Information contained on this website is provided with the understanding that Chicago Asthma Consortium, this site and its services, including all of the resources provided, serve informational purposes only. Only a doctor who is treating you can provide you with medical advice, examination, diagnosis or treatment. If you think you may have a medical emergency, call your doctor or 911 immediately. The Chicago Asthma Consortium does not endorse any medical or professional services referred to on this site or any links to this site. It also does not recommend or endorse any specific tests, products, procedures, opinions, or any other information that may be mentioned. While we try to keep the information on this site accurate, we cannot guarantee its accuracy, timeliness or completeness.

© 2023 Chicago Asthma Consortium

Powered by Wild Apricot Membership Software